| 11/16/2026 3:30 PM | BERNS PAUL L (1202769) Filed by Neumora Therapeutics (1885522) Subject | Form SCHEDULE 13G/A | |
| 11/16/2026 7:15 AM | Neumora Therapeutics (1885522) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/16/2026 7:03 AM | Neumora Therapeutics (1885522) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/30/2026 3:05 PM | Neumora Therapeutics (1885522) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/21/2026 6:08 PM | Milligan Michael Lee (1993953) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/21/2026 6:08 PM | Duncan Jason (1741553) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/21/2026 6:10 PM | BERNS PAUL L (1202769) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/21/2026 6:10 PM | Aurora Daljit Singh (1793971) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/21/2026 6:06 PM | Neumora Therapeutics (1885522) Issuer Pinto Joshua (1992595) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/21/2026 3:34 PM | Aurora Daljit Singh (1793971) Reporting Neumora Therapeutics (1885522) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/20/2026 3:22 PM | Aurora Daljit Singh (1793971) Reporting Neumora Therapeutics (1885522) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for NMRA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 08/19/2026 6:17 PM | Aurora Daljit Singh (1793971) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/19/2026 3:19 PM | Aurora Daljit Singh (1793971) Reporting Neumora Therapeutics (1885522) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/18/2026 3:32 PM | Aurora Daljit Singh (1793971) Reporting Neumora Therapeutics (1885522) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/17/2026 4:25 PM | Aurora Daljit Singh (1793971) Reporting Neumora Therapeutics (1885522) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/14/2026 6:23 AM | Neumora Therapeutics (1885522) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/14/2026 6:13 AM | Neumora Therapeutics (1885522) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/15/2026 7:15 AM | Neumora Therapeutics (1885522) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/29/2026 3:30 PM | Fust Matthew K (1397266) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 3:34 PM | Burow Kristina (1569248) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 3:21 PM | Ho Maykin (1646395) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 3:21 PM | Halawa Alaa (1992622) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 3:05 PM | Neumora Therapeutics (1885522) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/15/2026 4:16 PM | K2 HealthVentures Equity Trust LLC (1948604) Filed by Neumora Therapeutics (1885522) Subject | Form SCHEDULE 13G/A | |
| 05/07/2026 6:10 AM | Neumora Therapeutics (1885522) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/04/2026 1:08 PM | Invus Global Management, LLC (2005369) Filed by Neumora Therapeutics (1885522) Subject | Form SCHEDULE 13G/A | |
| 04/17/2026 3:04 PM | Neumora Therapeutics (1885522) Filer | Form DEF 14A | |
| 04/17/2026 3:05 PM | Neumora Therapeutics (1885522) Filer | Form DEFA14A | |
| 04/01/2026 3:10 PM | ARCH Venture Fund XII, L.P. (1906837) Filed by Neumora Therapeutics (1885522) Subject | Form SCHEDULE 13D/A | |
| 03/30/2026 6:20 AM | Neumora Therapeutics (1885522) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/30/2026 5:58 AM | Neumora Therapeutics (1885522) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/30/2026 6:07 AM | Neumora Therapeutics (1885522) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/19/2026 4:06 PM | Neumora Therapeutics (1885522) Issuer Pinto Joshua (1992595) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/19/2026 4:07 PM | Aurora Daljit Singh (1793971) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/19/2026 3:37 PM | Invus Global Management, LLC (2005369) Filed by Neumora Therapeutics (1885522) Subject | Form SCHEDULE 13G | |
| 02/11/2026 6:00 AM | Neumora Therapeutics (1885522) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/12/2026 6:00 AM | Neumora Therapeutics (1885522) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/09/2026 3:18 PM | Duncan Jason (1741553) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/09/2026 3:19 PM | Aurora Daljit Singh (1793971) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/09/2026 3:17 PM | BERNS PAUL L (1202769) Reporting Neumora Therapeutics (1885522) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/09/2026 3:18 PM | Neumora Therapeutics (1885522) Issuer Pinto Joshua (1992595) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Your book is inside (Ad) The "Sucker's Bet" Most New Options Traders Fall For
Most people who try options lose money the same way.
They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter.
Normally $29.97. Free today. Download your copy now. |
| 01/05/2026 5:44 AM | Neumora Therapeutics (1885522) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/05/2026 5:44 AM | Neumora Therapeutics (1885522) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/21/2025 3:05 PM | Neumora Therapeutics (1885522) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |